What's the most recent regulatory action in Diffuse large B-cell lymphoma refractory?

Most recent: Polatuzumab — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/diffuse-large-b-cell-lymphoma-refractory.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Diffuse large B-cell lymphoma refractory — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diffuse large B-cell lymphoma refractory (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Diffuse large B-cell lymphoma refractory, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Polivy	POLATUZUMAB VEDOTIN	Roche		B-cell antigen receptor complex-associated protein beta chain	2019-01-01
Treanda	BENDAMUSTINE	Baxter	Alkylating Drug	Histone deacetylase 6	2008-01-01
Polatuzumab	Polatuzumab	National Cancer Institute (NCI)		B-cell antigen receptor complex-associated protein beta chain, Tubulin beta
MONJUVI	TAFASITAMAB-CXIX	MORPHOSYS US INC		B-lymphocyte antigen CD19
Bendamustin	Bendamustin	Meir Medical Center		Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2
Xmab5574	tafasitamab	Morphosys Us Inc		B-lymphocyte antigen CD19	2020-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-18 — Polatuzumab · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Baxter · 1 drug in Diffuse large B-cell lymphoma refractory
MORPHOSYS US INC · 1 drug in Diffuse large B-cell lymphoma refractory
Meir Medical Center · 1 drug in Diffuse large B-cell lymphoma refractory
Morphosys Us Inc · 1 drug in Diffuse large B-cell lymphoma refractory
National Cancer Institute (NCI) · 1 drug in Diffuse large B-cell lymphoma refractory
Roche · 1 drug in Diffuse large B-cell lymphoma refractory

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diffuse large B-cell lymphoma refractory:

Cite this brief

Drug Landscape (2026). Diffuse large B-cell lymphoma refractory — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diffuse-large-b-cell-lymphoma-refractory. Accessed 2026-06-10.

Diffuse large B-cell lymphoma refractory full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing